Lake Street on Monopar Therapeutics (MNPR): attractive risk/reward entry point

April 21, 2026 8:52 AM

Lake Street analyst Chad Messer reiterated a Buy rating and $103.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found